The Newcastle Herald features Immvirx on its work to develop cutting-edge cancer therapies
Hunter-based biotech team ImmVirX is working on a private venture aiming to develop cutting-edge cancer therapies. ImmVirX was established with support from the University of Newcastle Research Associates, recruiting key research staff who were pivotal in Viralytics’ medical and commercial success. The University of Newcastle’s Professor Darren Shafren is the Chief Scientific Officer and Dr […]
New biotech venture going viral in battle against cancer
The scientific team behind Viralytics, a Hunter-based biotech firm bought in 2018 by Merck for a record $502 million, is reuniting for a new private venture aiming to develop cutting-edge cancer therapies. Read the full story here
